期刊
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
卷 3, 期 1, 页码 43-55出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsptsci.9b00097
关键词
Lipoxin A(4); resolution of inflammation; chronic inflammatory disorders; therapeutic target
资金
- National Health and Medical Research Council (NHMRC) of Australia [NHMRC APP1159460, APP1122176]
- Victorian Government's Operational Infrastructure Support Program
Several studies have shown that failure to resolve inflammation may contribute to the progression of many chronic inflammatory disorders. It has been suggested targeting the resolution of inflammation might be a novel therapeutic approach for chronic inflammatory diseases, including inflammatory bowel disease, diabetic complications, and cardiometabolic disease. Lipoxins [LXs] are a dass of endogenously generated mediators that promote the resolution of inflammation. Biological actions of LXs include inhibition of neutrophil infiltration, promotion of macrophage polarization, increase of macrophage efferocytosis, and restoration of tissue homeostasis. Recently, several studies have demonstrated that LXs and synthetic analogues protect tissues from acute and chronic inflammation. The mechanism includes down-regulation of pro-inflammatory cytokines and chemokines (e.g., interleukin-1 beta and tumor necrosis factor-alpha), inhibition of the activation of the master pro-inflammatory pathway (e.g., nuclear factor K-light-chain-enhancer of activated B cells pathway) and increased release of the pro-resolving cytokines (e.g., interleukin-10). Three generations of LXs analogues are well described in the literature, and more recently a fourth generation has been generated that appears to show enhanced potency. In this review, we will briefly discuss the potential therapeutic opportunity provided by lipoxin A(4) as a novel approach to treat chronic inflammatory disorders, focusing on cardiometabolic disease and the current drug development in this area.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据